Purespring Therapeutics has raised £80 million in an oversubscribed Series B financing
LONDON: Syncona Ltd’s portfolio company Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases has raised £80 million in...